Shrink Belly Fat and Protect Your Heart: The Science of Tesamorelin
If you have ever struggled with stubborn belly fat, you probably know how frustrating it can be to lose. But did you know that not all body fat is created equal?
Deep inside our bodies, wrapped around our internal organs, lies visceral adipose tissue (VAT). Unlike the softer fat that sits right under our skin, this deep visceral fat is directly linked to an increased risk of cardiovascular disease. Interestingly, obesity is also associated with reduced secretion of growth hormone.
This raises an exciting question: could boosting this hormone help target that dangerous deep belly fat? A fascinating 12-month study published in The Journal of Clinical Endocrinology & Metabolism explored exactly this concept.
The Study: Boosting Growth Hormone in Obese Adults
To understand how growth hormone impacts our waistlines and hearts, researchers conducted a randomized, double-blind, placebo-controlled trial.
- The Participants: The study involved 60 abdominally obese subjects. These individuals were specifically chosen because they had reduced growth hormone secretion.
- The Treatment: Participants were given either a placebo or 2 mg of tesamorelin once daily for a full 12 months. Tesamorelin is a growth hormone-releasing factor analog.
- The Goal: Researchers wanted to determine the effects of augmenting endogenous growth hormone secretion on body composition and cardiovascular disease risk indices.
The Results: What Happened After 12 Months?
The findings were incredibly promising for cardiovascular and metabolic health.
- Targeted Belly Fat Loss: The group taking tesamorelin saw a significant reduction in abdominal visceral adipose tissue (VAT) compared to the placebo group. Interestingly, it selectively targeted this deep fat without having any significant effects on subcutaneous fat.
- Healthier Arteries: Researchers assessed carotid intima-media thickness (cIMT) using ultrasounds. The tesamorelin group showed significant improvements in cIMT, indicating a positive impact on a key cardiovascular risk factor.
- Reduced Inflammation: C-reactive protein, a key marker for systemic inflammation, significantly decreased in the treated group.
- Lower Triglycerides: The tesamorelin treatment successfully lowered triglycerides compared to the placebo group.
Is It Safe for Blood Sugar?
One common concern with altering growth hormone pathways is the potential to negatively affect blood sugar levels. However, this study delivered reassuring news.
- Stable Blood Sugar: Researchers found no changes in fasting glucose or 2-hour glucose levels.
- Healthy A1C: The treatment caused no changes in glycated hemoglobin.
- Safety Profile: There were no serious adverse events reported. Additionally, the rate of adverse events did not differ between the treatment and placebo groups.
What This Means For You
This study demonstrates that among obese subjects with reduced growth hormone, using a growth hormone-releasing factor like tesamorelin selectively reduces deep belly fat. Furthermore, it improves triglycerides, reduces inflammation, and improves carotid intima-media thickness without aggravating glucose levels. While tesamorelin is a specific medical intervention, this research highlights how addressing internal hormone imbalances can have profound, targeted effects on our metabolic health.
Sources Used
- : Makimura, H., Feldpausch, M. N., Rope, A. M., Hemphill, L. C., Torriani, M., Lee, H., & Grinspoon, S. K. (2012). Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. The Journal of Clinical Endocrinology and Metabolism, 97(12), 4769–4779. https://pubmed.ncbi.nlm.nih.gov/23015655/